Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marizyme Inc. MRZM

Marizyme is a multi-technology biomedical company dedicated to the accelerated development & commercialization of medical device technologies that improve patient health outcomes. Marizyme seeks to leverage their healthcare innovations biomedical technologies: DuraGraft®, Krillase®, & MATLOCTM to address critical market gaps & offer transformative potential to wide range of issues including coronary artery bypass graft (CABG) surgery, fat grafting, pet health, and chronic kidney disease (CKD).


Recent & Breaking News (OTCQB:MRZM)

    Statera Biopharma Announces Changes to Board of Directors

    GlobeNewswire February 25, 2022

    Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office

    GlobeNewswire January 5, 2022

    Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing

    GlobeNewswire December 23, 2021

    Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress

    GlobeNewswire December 3, 2021

    Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories

    GlobeNewswire December 3, 2021

    Marizyme is Pleased to Announce the Appointment of David Barthel as CEO

    GlobeNewswire November 16, 2021

    Marizyme, Inc. Issues Letter to Shareholders

    PR Newswire March 31, 2021

    Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera

    PR Newswire March 4, 2021

    Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf to Board

    PR Newswire February 4, 2021

    Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems

    PR Newswire February 1, 2021

    Marizyme Announces Approval for DuraGraft® in India

    PR Newswire January 14, 2021

    Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf

    PR Newswire January 11, 2021

    Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P. Morgan Week 2021"

    PR Newswire January 7, 2021

    Marizyme, Inc. Expands Executive Team, Board of Directors

    PR Newswire December 4, 2020

    Marizyme, Inc. Appoints Dr. Neil J. Campbell, as CEO, President and Member of Board of Directors

    PR Newswire November 6, 2020

    Marizyme and SBH Nutrition Science Agree to Develop Krillase(R) Based Dental Products for Pets

    Accesswire October 27, 2020

    Marizyme Announces European DuraGraft(R) Registry Results Presented at the European Association for Cardio-Thoracic Surgery (EACTS) 34th Annual Virtual Meeting

    Accesswire October 9, 2020

    Marizyme, Inc. Completes Acquisition of Somahlution, Inc. and Raises $7.0 Million in Private Placement

    Accesswire September 29, 2020

    Marizyme, Inc., Agrees to Distribute Somahlution's DuraGraft Products in South America and Mexico

    PR Newswire October 11, 2019